

# DEFIBROTIDE

BRAND NAME	DEFITELIO
DRUG CLASS	Antithrombotic
AVAILABILITY	Vial contains 200 mg/2.5 mL of defibrotide. Also contains sodium citrate dihydrate, hydrochloric acid and sodium hydroxide. Contains less than 1 mmol (23 mg) of sodium. The solution is clear light yellow to brown. <sup>1</sup>
pH	No information
PREPARATION	Dilute before use <sup>1</sup>
STABILITY	Vial: store below 25 °C. Do not freeze. <sup>1</sup> Infusion solutions: stable for 24 hours at 25 °C or 2 to 8 °C. <sup>1,2</sup>
ADMINISTRATION	
<b>IM injection</b>	Not recommended
<b>SUBCUT injection</b>	Not recommended
<b>IV injection</b>	Not recommended <sup>1</sup>
<b>IV infusion</b>	Dilute the dose to a concentration of 4–20 mg/mL with a compatible fluid, mix gently. Infuse over 2 hours. Use a 0.2 micrometre inline filter. <sup>1</sup>
COMPATIBILITY	
<b>Fluids</b>	Glucose 5% <sup>1</sup> , sodium chloride 0.9% <sup>1</sup>
<b>Y-site</b>	Visually compatible for 4 hours at <b>8 mg/mL</b> : aciclovir <sup>3</sup> , albumin <sup>3</sup> , amoxicillin <sup>3</sup> , caspofungin <sup>3</sup> , ceftazidime <sup>3</sup> , ceftriaxone <sup>3</sup> , ciclosporin <sup>3</sup> , ciprofloxacin <sup>3</sup> , clonazepam (0.02 mg/mL) <sup>3</sup> , fluconazole <sup>3</sup> , foscarnet <sup>3</sup> , fosfomycin <sup>3</sup> , ganciclovir <sup>3</sup> , heparin sodium <sup>3</sup> , hydrocortisone sodium succinate <sup>3</sup> , imipenem-cilastatin <sup>3</sup> , mesna <sup>3</sup> , methylprednisolone sodium succinate <sup>3</sup> , metronidazole <sup>3</sup> , naloxone <sup>3</sup> , ondansetron <sup>3</sup> , paracetamol <sup>3</sup> , teicoplanin <sup>3</sup> , tranexamic acid <sup>3</sup> , trimethoprim-sulfamethoxazole <sup>3</sup>
INCOMPATIBILITY	
<b>Fluids</b>	No information
<b>Drugs</b>	Amikacin <sup>3</sup> , mycophenolate mofetil <sup>3</sup> , nicardipine <sup>3</sup> , tobramycin <sup>3</sup> , vancomycin <sup>3</sup>
SPECIAL NOTES	Rapid administration may cause flushing or a sensation of generalised heat. <sup>1</sup> Monitor the patient for signs of bleeding. <sup>1</sup>

## REFERENCES

1. Product information, Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 22/10/2020.
2. Defitelio. Summary of product characteristics. Villa Guardia, Italy: Gentium. Approved 18/10/2013. Updated 26/07/2018. Available from [www.ema.europa.eu](http://www.ema.europa.eu). Accessed 21/05/2019.
3. Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. *Am J Health-Syst Pharm* 2014; 71: 1288-91.